Table 1.
IgG and IgA serum levels and PRNT50 titers against SARS-CoV-2 of COVID-19 patients and non COVID-19 patients.
| patient ID | clinical progress | 1 week post symptom onset * | 2/3 weeks post symptom onset | 9/10 weeks post symptom onset | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S1 IgG OD ratio | S1 IgA OD ratio | NCP IgG OD ratio | S1 IgG OD ratio | S1 IgA OD ratio | NCP IgG OD ratio | PRNT50§ | S1 IgG OD ratio | S1 IgA OD ratio | NCP IgG OD ratio | PRNT50§ | ||
| patient 1 | mild | 0.18 | 0.34 | 0.22 | 1.46 | 3.04 | 1.65 | >640# | 1.25 | 0.94 | 1.41 | 160 |
| patient 2 | mild | 0.22 | 0.33 | 0.06 | 1.56 | 3.58 | 0.83 | 320# | 3.91 | 3.82 | 0.91 | 80 |
| patient 3 | mild | 0.24 | 0.87 | 0.10 | 3.26 | 5.77 | 0.62 | >640# | 2.38 | 2.10 | 0.53 | 80 |
| patient 4 | mild | 0.17 | 0.17 | 0.18 | 0.77 | 2.35 | 0.43 | 160# | 1.24 | 0.82 | 0.41 | 80 |
| patient 7 | mild | 0.18 | 0.18 | 0.30 | 10.17 | >11 | 6.06 | >1280# | 7.79 | >14 | 5.85 | >640 |
| patient 8 | mild | 0.17 | 0.15 | 0.05 | 3.96 | 5.94 | 0.43 | >320# | 5.23 | 3.59 | 1.26 | 320 |
| patient 10 | mild | 0.26 | 0.98 | 0.06 | 0.28 | 1.12 | 0.33 | >40# | 0.87 | 2.31 | 1.09 | 160 |
| patient 14 | mild | 7.93 | 9.75 | 5.30 | >40# | |||||||
| patient 16 | mild | 0.84 | 1.32 | >320# | ||||||||
| 20-03-CV-09 | severe | 7.96 | >13 | 4.24 | 320 | |||||||
| 20-03-CV-11 | severe | 8.1 | >12 | 5.03 | >640 | |||||||
| 20-03-CV-12 | severe | 8.14 | 13.28 | 6.58 | 80 | |||||||
| 20-03-CV-13 | severe | 3.49 | >9 | >9 | 320 | |||||||
| 20-03-CV-16 | severe | 7.01 | >13 | 4.74 | 640 | |||||||
| 20-03-CV-20 | severe | 8.26 | 12.15 | 6.38 | 640 | |||||||
| 20-03-CV-25 | severe | 12.13 | 13.14 | 6.25 | >640 | |||||||
| C01 | control | 0.16 | 0.21 | |||||||||
| C02 | control | 0.47 | 1.07 | |||||||||
| C03 | control | 0.22 | 0.5 | |||||||||
| C04 | control | 0.24 | 0.37 | |||||||||
| C05 | control | 0.35 | 0.25 | |||||||||
| C06 | control | 0.4 | 0.98 | |||||||||
| C07 | control | 0.3 | 0.42 | |||||||||
OD, optical density *control sera were obtained from healthy volunteers with no reported symptoms.
#Data were previously published by Wölfel et al. (29); §PRNT values are given as reciprocal titers.